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1The Voice of the Editor-in-Chief
Dear Colleagues,
The 52nd Congress of the European Association for 
the Study on Diabetes (EASD) was held on 12–16 Sep-
tember 2016 in Munich. As always, the Congress was 
a platform for the participants to exchange the latest 
knowledge and experience in the field of diabetes. This 
meeting provided the opportunity to update the cur-
rent knowledge on diabetes, both in terms of basic sci-
ences and practical care of patients with carbohydrate 
metabolism disturbances, based on the results of recent 
clinical trials — randomised trials and supplementary 
observational studies.
Based on the trials performed in the recent years, 
new groups of hypoglycaemic drugs were introduced, 
such as incretin-based agents [glucagon-like pep-
tide-1 (GLP-1) agonists and dipeptidyl peptidase-4 in-
hibitors (DPP-4), also called gliptins] and sodium-glu-
cose co-transporter-2 (SGLT-2) inhibitors, also called 
flozins. These drugs were included in recent standards 
of care and the guidelines on the management of 
diabetic patients. These drugs used on every stage of 
diabetes, both in monotherapy and in combination 
with other oral glucose-lowering agents and/or insu-
lin, give hope for the change of treatment philosophy 
and improvement of patients’ quality of life. During 
the Congress, I listened with great interest the discus-
sions about clinical trials whose results were critical 
for the change of the pharmacotherapy of diabetes 
and abovementioned treatment philosophy. These 
landmark trials are: the LEADER study with liraglutide 
(a GLP-1 agonist) and the EMPA-REG-OUTCOME study 
that assessed empagliflozin (SGLT-2 inhibitor). Particu-
larly interesting in this context are SGLT-2 inhibitors, 
because they reduce renal glucose reabsorption and, 
thereby, increase urinary glucose excretion. Their action 
is independent from insulin, both in terms of insulin 
secretion and action. The EMPA-REG OUTCOME is 
a long-term clinical trial aimed to assess the effect of 
therapy with empagliflozin on cardiovascular outcomes 
in high cardiovascular risk patients with type 2 dia-
betes. This is undoubtedly the first trial that showed 
unequivocally that this drug added to glucose lowering 
therapy significantly reduced the risk of cardiovascular 
episodes. Importantly, the trial was designed specifically 
to evaluate such results.
The results of the EMPA-REG OUTCOME trial con-
cerning microvascular complications of diabetes were 
also widely commented during the Congress, because 
they revealed significant reduction in the risk of diabetic 
nephropathy development and progression. It is postu-
lated that this effect may result from the drug’s influ-
ence on intraglomerular pressure via afferent arteriole 
constriction. Moreover, this finding is a contribution to 
the discussion about potential combination of flozins 
and angiotensin converting enzyme inhibitors, which 
in turn have nephroprotective effect via glomerular 
efferent arteriole dilation.
Here, it should be mentioned that also the LEADER 
trial, that assessed cardiovascular safety of one of 
GLP-1 agonists, liraglutide, in the population of type 2 
diabetes patients with high risk of major cardio-
vascular event, showed significant risk reduction of 
cardiovascular death. Equally exciting were observa-
tions concerning semaglutide and the SUSTAIN 6 trial, 
especially considering the fact that this is the first oral 
GLP-1 agonist, thanks to conformulation with the ab-
sorption enhancer SNACK. Similarly, there were high 
expectations related to a new formulation of another 
GLP-1 agonist, exenatide — ITCA 650, that provides 
significantly prolonged action and, importantly, reduces 
fluctuations of blood glucose, which itself unfavour-
ably affects the risk of development and progression 
of cardiovascular complications and the patients’ 
quality of life.
Despite large-scale preventive interventions, dia-
betes remains a significant public health problem that 
becomes increasingly important both from clinical and 
epidemiological point of view. Our knowledge about 
diabetes becomes deeper, which results in important 
changes in our understanding of the disease and in 
treatment schedules, but the more we know, the more 
we are convinced that we are far away from getting 
the full information.
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